International School of Clinical Oncology – ISCO shared a series of posts on Facebook about the speakers on the upcoming ISCO Congress 2026:
Place: Cairo Marriott Hotel
Date: 23–24 April 2026
Organized By:
Cavallo D’Oro Perfect Touch Events
1. “We are thrilled to announce that Prof. Alessandra Gennari will be a distinguished speaker in the “Breast Cancer: Advances in Systemic Treatment of Advanced TNBC” session at this year’s ISCO!
Prof. Gennari is Professor of Oncology at the University of Eastern Piedmont (UPO) and Head of the Division of Oncology at Maggiore University Hospital, Novara, Italy. She also leads the Laboratory of Immuno-Oncology at the UPO-CAAD Center for Immune and Allergic Diseases. Her expertise includes molecular and therapeutic innovation in breast cancer, focusing on individualized drug responsiveness, endocrine responsiveness imaging by PET-CT with 18F-FES, and immunotherapy in metastatic breast cancer. She has authored over 100 peer-reviewed publications and is the lead author of the ESMO Metastatic Breast Cancer (MBC) Guidelines.
Join us in welcoming Prof. Gennari as she shares her insights and research with us!”
2. “We are thrilled to announce that Prof. Alexandra Leary will be a distinguished speaker in the “Gynecology Session: Integrating Molecular Classification into EC Management – Oncologist Perspective” at this year’s ISCO!
Prof. Leary is Deputy Head of the Department of Medical Oncology and a gynecological cancer specialist at Gustave Roussy, France, where she chairs the GINECO group dedicated to clinical trials in gynaecological oncology. Her expertise focuses on early drug development for ovarian, cervical, and endometrial cancers. Trained at the Royal Marsden Hospital in London, she holds a PhD in Molecular Biology from the Institute of Cancer Research, University of London. She is a faculty member of ESMO and served as gynaecology programme coordinator for ESMO 2022 and ESMO Asia 2023. She is principal investigator or co-investigator of nearly 100 Phase I–III clinical trials.
Join us in welcoming Prof. Leary as she shares her insights and research with us!”
3. “We are thrilled to announce that Prof. Alina Danu will be a distinguished speaker in the Hematology Session: “Myeloma Highlights and Impact on Practice in 2026” at this year’s ISCO!
Prof. Danu is a hematologist at Gustave Roussy Cancer Campus, France, affiliated with the Lymphoid Hemopathy Committee. She specializes in the diagnosis and treatment of lymphoid malignancies and is actively involved in both clinical care and research at one of Europe’s leading cancer centers.
Join us in welcoming Prof. Danu as she shares her insights and research with us!”
4. “We are thrilled to announce that Prof. Antonio Passaro will be a distinguished speaker in the Thoracic Session: “Current-edge Treatment Advances for Neoadjuvant/Adjuvant Treatment of Early Driver Mutated NSCLC” at this year’s ISCO!
Prof. Passaro is a Senior Staff Physician at the Division of Thoracic Oncology, European Institute of Oncology (IEO), Milan, Italy, with a PhD in molecular medicine. His clinical and research expertise focuses on targeted therapies and immunotherapy in non-small cell lung cancer (NSCLC), with an emphasis on predictive biomarkers and driver alterations. An active ESMO faculty member for Lung and other Thoracic Tumours since 2019, he served as Chair of the ESMO Press and Media Affairs Committee from 2021 to 2024 and is Associate Editor of the Lung Cancer Journal (Elsevier, from 2022). He has authored more than 170 peer-reviewed publications and is actively involved in translational research and clinical trials in thoracic oncology.
Join us in welcoming Prof. Passaro as he shares his insights and research with us!”
5. “We are thrilled to announce that Prof. Axel Le Cesne will be a distinguished speaker in the Sarcoma Session: “Overview of Important Updates in STS 2026” at this year’s ISCO!
Prof. Le Cesne is Head of the International Department at Gustave Roussy Cancer Campus and a leading expert in soft tissue and bone sarcomas. He is co-chair of the French Sarcoma Group, an active member of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), and was a member of the Board of Directors of the Connective Tissue Oncology Society (2010–2013). Elected to the French Academy of Medicine in 2014, he is a member of ASCO and ESMO and has authored more than 320 research articles on sarcomas, gastrointestinal stromal tumors, lung and breast cancer, immunotherapy, and gene therapy.
Join us in welcoming Prof. Le Cesne as he shares his insights and research with us!”
6. “We are thrilled to announce that Prof. Benjamin Besse will be a distinguished speaker in the Thoracic Session: “Outcomes With Perioperative Immunotherapy in Resectable NSCLC” at this year’s ISCO!
Prof. Besse is Director of Clinical Research at Gustave Roussy Cancer Campus and Professor of Medical Oncology at the University of Paris-Saclay, France. A specialist in thoracic malignancies, his research focuses on molecular profiling to personalise treatment, circulating biomarkers, and early drug development in thoracic tumours including rare subtypes such as NUT carcinomas and thymic malignancies. He has authored more than 500 peer-reviewed publications and served as principal investigator of more than 30 Phase I–III clinical trials over the past five years. He coordinates the French network for thymic malignancies (RYTHMIC) and was elected President-Elect of the EORTC in July 2025, with the presidency assumed in June 2026. He is a member of ASCO, IASLC, and ESMO.
Join us in welcoming Prof. Besse as he shares his insights and research with us!”
7. “We are thrilled to announce that Prof. Cristina Castilla Llorente will be a distinguished speaker in the Hematology Session: “CAR-T Cells When Irreplaceable in Lymphoid Neoplasms: Role for NHL, MM, HL in 2026?” at this year’s ISCO!
Prof. Castilla Llorente is a hematologist at Gustave Roussy Cancer Campus Grand Paris and a member of the Scientific Committee of the French National Reference Centre for hematology. She specializes in hematological malignancies and allogeneic stem cell transplantation, contributing to both clinical care and translational research.
Join us in welcoming Prof. Castilla Llorente as she shares her insights and research with us!”
8. “We are thrilled to announce that Prof. Elizabeth Smyth will be a distinguished speaker in the GIT Session: “Is PD-L1 Expression a Good Predictor of Survival Benefit in Patients With Advanced Gastroesophageal Cancer Treated With Immunotherapy?” at this year’s ISCO!
Prof. Smyth is a Consultant Medical Oncologist and GI Oncology Lead at Oxford University Hospitals NHS Foundation Trust, specialising in oesophagogastric cancer. In August 2025 she was elected ESMO Director of Education, responsible for shaping ESMO’s global oncology education programmes. She also serves as Chair of the ESMO Guidelines Committee, Chair of the EORTC GI Trials Group (2024–2027), and Clinical Lead at the Oxford Clinical Trials Office (OCTO), where she supports the development and governance of academic oncology trials. She trained in Dublin, New York (Memorial Sloan Kettering), and London (Royal Marsden), and holds an MD(Res) from the Institute of Cancer Research. She has published more than 200 peer-reviewed manuscripts — with over 23,000 citations — was subject editor for the ESMO Gastric and Oesophageal Cancer Guidelines, and is a founding member and trustee of the UK and Ireland Oesophagogastric Cancer Group (UKIOG, 2022).
Join us in welcoming Prof. Smyth as she shares her insights and research with us!”
9. “We are thrilled to announce that Prof. Fabrice André will be a distinguished speaker in the following sessions at this year’s ISCO!
Breast Cancer Session: “Evolving Strategies in Management of Advanced HR+ HER- Advanced Breast Cancer Post CDK4/6 Progression”
BREAST 1 / Precision Medicine Session: “Navigating the Evolving Landscape of Biomarkers in Luminal Advanced Breast Cancer”
Prof. André is President of the European Society for Medical Oncology (ESMO) for the 2025–2026 term and Director of Research at Gustave Roussy, where he also serves as Professor in the Department of Medical Oncology. A specialist in breast cancer and precision oncology, he leads the Inserm U981 research unit on predictive biomarkers and personalised therapies. He is the author or co-author of more than 350 scientific publications and is listed among the Highly Cited Researchers (Web of Science). Ranked among the 25 most influential figures in precision medicine by BIS Research, he is a recipient of the ASCO Young Investigator and Career Development Awards and served as Editor-in-Chief of Annals of Oncology from 2017 to 2023.
Join us in welcoming Prof. André as he shares his insights and research with us!”
10. “We are thrilled to announce that Prof. Fabrice Barlesi will be a distinguished speaker in the Thoracic Session: “Unresectable Stage III NSCLC: Patient Selection and Treatment Options” at this year’s ISCO!
Prof. Barlesi is General Director of Gustave Roussy and Professor specialising in thoracic oncology at Paris-Saclay University. He formerly headed the Multidisciplinary Oncology and Innovative Therapies Department at Nord Hospital in Marseille and established the Marseille Centre for Early Trials in Oncology (CLIP2). A co-founder of the Marseille Immunopôle network and leader of the international PIONeeR project on resistance to anti-PD1/L1 immunotherapy in lung cancer, he has authored approximately 400 articles in international journals. He received the prestigious ESMO/IASLC Heine H. Hansen Prize in 2018 and is listed among the world’s most influential researchers (Highly Cited Researchers, Web of Science, 2024).
Join us in welcoming Prof. Barlesi as he shares his insights and research with us!”
11. “We are thrilled to announce that Prof. Hamdy Abdelazim will be a distinguished speaker in the BREAST 1 / Precision Medicine Session: “Precision Medicine in Breast Cancer” at this year’s ISCO!
Prof. Hamdy Abdelazim is a Professor of Clinical Oncology at Cairo University and founder of the Cairo Cure Cancer Center. As Chairman of Kasr Al-Ainy School of Oncology (KASO) — the official cancer education organisation of the Department of Oncology, Faculty of Medicine, Cairo University — he has been instrumental in advancing oncology training in Egypt. He also serves as President of the Africa Middle East Cancer Research Intergroup, promoting collaborative cancer research across the region.
Join us in welcoming Prof. Abdelazim as he shares his insights and research with us!”
12. “We are thrilled to announce that Prof. Javier Cortes will be a distinguished speaker in the BREAST 1 / Precision Medicine Session: “New Era in the Management of Advanced HER2 Positive Breast Cancer” at this year’s ISCO!
Prof. Javier Cortés (MD, PhD) is a medical oncologist and Head of the International Breast Cancer Center (IBCC) in Barcelona, Spain, and Senior Clinical Investigator of the Breast Cancer Research Programme at the Vall d’Hebron Institute of Oncology (VHIO). A globally recognised expert in breast cancer, he has served as principal investigator in landmark international clinical trials leading to the approval of pertuzumab, eribulin, and sacituzumab govitecan for metastatic breast cancer. He has authored more than 350 peer-reviewed publications and presented at over 800 international conferences. He is a member of ESMO, ASCO, and SEOM.
Join us in welcoming Prof. Cortés as he shares his insights and research with us!”
13. “We are thrilled to announce that Prof. Jean-Henri Bourhis will be a distinguished speaker in the Hematology Session: “Place of Auto/Allo BMT in Lymphoid Neoplasm in 2026” at this year’s ISCO!
Prof. Jean-Henri Bourhis is a renowned hematologist at Gustave Roussy Cancer Campus and Head of the Hematopoietic Stem Cell Transplant Committee. He specialises in hematopoietic stem cell transplants — both autologous and allogeneic — in patients with hematological cancers, managing complex cases across a broad spectrum of malignant haematological conditions.
Join us in welcoming Prof. Bourhis as he shares his insights and research with us!”
14. “We are thrilled to announce that Prof. Jonathan Ledermann will be a distinguished speaker in the Gynecology Session: “Long Term Outcomes of PARPi in Ovarian Cancers, OS and Post Progression Insights” at this year’s ISCO!
Prof. Jonathan Ledermann (BSc, MD, FRCP, FMedSci) is Professor of Medical Oncology at the UCL Cancer Institute, University College London, and Director of the Cancer Research UK and UCL Cancer Trials Centre. He has specialised in gynecological cancers — particularly ovarian cancer — for more than 35 years and has led many national and international practice-changing clinical trials including the pivotal olaparib PARP inhibitor trials (SOLO2/ENGOT-Ov21) published in The Lancet Oncology and the New England Journal of Medicine. A founding member of ENGOT (European Network of Gynaecological Oncological Trial groups) and a NIHR Senior Investigator, he serves as Vice President of ESGO (European Society of Gynaecological Oncology) and has chaired the GCIG Rare Tumour Working Group and the NCRI UK Gynaecological Cancer Trials Group. He is the recipient of the 2025 IGCS Lifetime Achievement Award.
Join us in welcoming Prof. Ledermann as he shares his insights and research with us!”
15. “We are thrilled to announce that Prof. Julien Taieb will be a distinguished speaker in the GIT Session: “Adjuvant Treatment for Colon Cancer: Updates on What Has Been Achieved? Where Are We Going?” at this year’s ISCO!
Prof. Julien Taieb (MD, PhD) is Head of the Gastroenterology and Digestive Oncology Department at the Georges Pompidou European Hospital (AP-HP) and Professor of Medicine at Université Paris Cité, France. He is Founder of AGEO, the French research group dedicated to gastrointestinal tumours, and holds positions on the administrative councils of ESMO, FFCD, and SNFGE. He serves as Faculty Coordinator for the ESMO Gastrointestinal Tumours Colorectal Faculty and has been a member of the ESMO Nomination Committee since 2018. His main research areas are non-metastatic and metastatic colorectal cancer, pancreatic cancer, and the use of circulating tumour DNA (ctDNA) as a prognostic and predictive biomarker. He has led more than 10 national and international Phase II and III studies and over 20 Phase I/II studies, and has authored 3 educational books and more than 300 peer-reviewed publications, with over 42,000 citations. He is a regular reviewer for The Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, and the European Journal of Cancer.
Join us in welcoming Prof. Taieb as he shares his insights and research with us!”
16. “We are thrilled to announce that Prof. Karim Fizazi will be a distinguished speaker in the Genitourinary Session: “mHSPC: Treatment Escalation/DeEscalation: When and How?” at this year’s ISCO!
Prof. Karim Fizazi is a medical oncologist and Professor of Oncology at the University of Paris-Saclay, France. Appointed General Director of Centre Oscar Lambret in Lille from March 2026, he previously led the Genitourinary Oncology Group and the International Academic Network at Gustave Roussy Cancer Campus for many years. A globally recognised expert in prostate and testicular cancers, he has chaired a series of practice-changing international trials including LATITUDE (abiraterone in metastatic prostate cancer), ARAMIS (darolutamide in non-metastatic CRPC), TRITON-3, and the PEACE-1 and PEACE-2 Phase III trials under the PEACE consortium he founded in 2013. He is President of the French Genitourinary Tumour Group (GETUG) and was elected ESMO Director of Public Policy in the 2025 ESMO elections. He is Associate Editor of the European Journal of Cancer and has authored more than 500 scientific publications.
Join us in welcoming Prof. Fizazi as he shares his insights and research with us!”
17. “We are thrilled to announce that Prof. Laurence Albiges will be a distinguished speaker in the Genitourinary Session: “Current and Emerging Therapeutic Approaches for nccRCC” at this year’s ISCO!
Prof. Laurence Albiges is Head of the Medical Oncology Department at Gustave Roussy Cancer Campus (appointed October 2021) and Professor of Medical Oncology at the University of Paris-Saclay, France. Her clinical and research focus centres on metastatic renal cell carcinoma (RCC) and rare forms of non-clear cell renal carcinoma. She has contributed to the development of targeted agents and immune checkpoint inhibitors for RCC and has published over 350 peer-reviewed articles, being listed among the Highly Cited Researchers by Clarivate since 2023. She has served on the EAU RCC guidelines panel (2016–2024), the ESMO RCC guidelines panel, and coordinated the ESMO Genitourinary (non-prostate) Faculty (2020–2024). Since May 2023, she is the PI of the Horizon Europe-funded CARE1 project — an eight-year multicentre European trial across eight countries focused on optimising first-line treatment strategies for metastatic kidney cancer. She is a member of the GETUG steering committee and has received the Conquer Cancer Foundation Merit Award (ASCO GU 2015).
Join us in welcoming Prof. Albiges as she shares her insights and research with us!”
18. “We are thrilled to announce that Prof. Loïc Renaud will be a distinguished speaker in the Hematology Session: “2026 Review: Key Updates in Hodgkin Lymphoma” at this year’s ISCO!
Prof. Loïc Renaud is an oncologist and hematologist in the Department of Hematology at Gustave Roussy, France, specialising in chronic lymphoproliferative disorders including Hodgkin and non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). He is also a Post-Doctoral Fellow in the Landau Lab at Weill Cornell Medical College, New York, with research focused on lymphoma and CLL from first-line therapy to Phase I trials, including therapeutic intensification and CAR-T cell therapies. An active member of LYSA since 2021, he has contributed to clinical recommendations for Hodgkin lymphoma and DLBCL and serves as co-coordinator of PMBL recommendations. He is principal investigator and co-investigator of multiple Phase II and III trials in lymphoid hematological diseases.
Join us in welcoming Prof. Renaud as he shares his insights and research with us!”
19. “We are thrilled to announce that Prof. Lorenza Landi will be a distinguished speaker in the Thoracic Session: “ALK-unlocked: Key to Management Choice in NSCLC” at this year’s ISCO!
Prof. Lorenza Landy is a medical oncologist and Director of the Clinical Trials Unit at the IRCCS Regina Elena National Cancer Institute in Rome, Italy. She is also affiliated with USL Toscana Nord-Ovest in Livorno and is a member of the Italian Association of Medical Oncology (AIOM). Her work spans clinical trial design, coordination, and management in oncology, contributing to both national and international research initiatives in cancer treatment.
Join us in welcoming Prof. Landy as she shares her insights and research with us!”
20. “We are thrilled to announce that Prof. Marc Spielmann will be a distinguished speaker in the Breast Cancer Session: “Case Discussion HER2 Low Advanced Breast Cancer” at this year’s ISCO!
Prof. Marc Spielmann is a medical oncologist specialising in breast cancer and Director of the Institut Français du Sein (French Breast Institute) in Paris. He spent the majority of his career at Gustave Roussy Cancer Campus, where he was Head of the Department of Cancerology and Breast Pathology (Oncologie Médicale et Pathologie Mammaire) and, subsequently, Medical Director of the International Affairs Division. He has authored more than 290 peer-reviewed scientific and medical publications in national and international journals, with over 10,000 citations, and has served on the scientific committees of numerous national and international courses and congresses. He is a member of ASCO, ESMO, the Société Française de Sénologie et de Pathologie Mammaire (SFSPM), and the Société Française de Mastologie et de Pathologie Mammaire (SFMPP).
Join us in welcoming Prof. Spielmann as he shares his insights and research with us!”
21. “We are thrilled to announce that Prof. Maria Elena Elez will be a distinguished speaker in the GIT Session: “Predictive Biomarker Under Study in Colorectal Cancer” at this year’s ISCO!
Prof. Maria Elena Élez (MD, PhD) is a Medical Oncology Consultant at Vall d’Hebron University Hospital and Principal Investigator of the Colorectal Cancer and Precision Oncology Programme at the Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. A leading specialist in metastatic colorectal cancer (CRC), her research focuses on the RAS/BRAF pathway, particularly BRAF V600E-mutant CRC, liquid biopsy-based monitoring of ctDNA, and molecular classification of colorectal tumours. She led the BREAKWATER trial, whose results were published in the New England Journal of Medicine (ASCO 2025), and has published landmark studies in Nature Medicine and the NEJM. She is actively involved in European collaborative projects and has served in educational leadership roles at SEOM and VHIO.
Join us in welcoming Prof. Élez as she shares her insights and research with us!”
22. “We are thrilled to announce that Prof. Patricia Pautier will be a distinguished speaker in the Gynecology Session: “Updates in Treatment of Uterine Cervix Cancers” at this year’s ISCO!
Prof. Patricia Pautier has been a medical oncologist at Gustave Roussy since 2000 and has headed the Multidisciplinary Gynecological Oncology Committee since 2015. She specialises in ovarian cancer, uterine cancer, and rare gynecological tumours, and is co-coordinator of the national network for rare gynecological tumours. A member of GINECO (National Investigators Group for the Study of Ovarian Cancers) and the French Sarcoma Group (GSF), she is the principal investigator of Phase II and III clinical trials in gynecological tumours and sarcomas — with a particular focus on uterine sarcomas, especially leiomyosarcomas. She is also a member of the European EURACAN network for rare gynecological tumours and sarcomas, and holds active memberships in ESMO, ESGO, and ASCO.
Join us in welcoming Prof. Pautier as she shares her insights and research with us!”
23. “We are thrilled to announce that Prof. Patrice Carde will be a distinguished speaker in the Hematology Session: “Update on treatment
landscape in CLL” at this year’s ISCO!
Prof. Patrice Carde is an Expert Consultant in the Department of Hematology at Gustave Roussy Cancer Campus and Former Head of the Medical Oncology and Onco-Hematology Department. He has also served as Fellow and Visiting Professor in Medical Oncology at Stanford Cancer Center, California, and as Professor at the College of Medicine, Paris Hospitals. With more than 200 publications in hematology, he is a reviewer for the Journal of Clinical Oncology and has chaired hematology societies including the American Society of Hematology (ASH) and the Société Française d’Hématologie.
Join us in welcoming Prof. Carde as he shares his insights and research with us!”
24. “We are thrilled to announce that Prof. Stephane De Botton will be a distinguished speaker in the Hematology Session: “Update on Treatment Landscape in CML” at this year’s ISCO!
Prof. Stéphane De Botton is Head of the Hematology Department and Head of the Myeloid Pathology Committee at Gustave Roussy Cancer Campus, France. A leading expert in hematological oncology, he specialises in myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes. He has led and participated in several landmark clinical trials in haematology and has contributed extensively to the scientific literature through publications in peer-reviewed international journals. His research has received international recognition and awards.
Join us in welcoming Prof. De Botton as he shares his insights and research with us!”
25. “We are thrilled to announce that Prof. Thierry Andre will be a distinguished speaker in the GIT Session: “ICI in the Treatment of GI Tumors” at this year’s ISCO!
Prof. Thierry André is Professor of Medical Oncology at Sorbonne Université in Paris and Head of the Medical Oncology Department at Saint Antoine Hospital (AP-HP), a position he has held since 2011. He is Past President and current member of the Scientific Committee of the ARCAD Foundation (Aide et Recherche en Cancérologie Digestive), and Founder and Vice President of the GERCOR multidisciplinary oncology research group, where he chairs the scientific committee. A leading specialist in gastrointestinal malignancies — particularly MSI-H/dMMR colorectal cancer and immunotherapy — he has served as principal investigator of numerous Phase I, II, and III clinical trials including the CheckMate 8HW study. He has authored more than 570 peer-reviewed publications indexed on PubMed. He is a member of ESMO, ASCO, and the ACCENT group, and is affiliated with INSERM’s Microsatellite Instability and Cancer team at the Centre de Recherche Saint-Antoine, Paris.
Join us in welcoming Prof. André as he shares his insights and research with us!”
26. “We are thrilled to announce that Prof. Thierry Le Chevalier will be a distinguished speaker in the Thoracic Session: “Current Treatment Landscape in SCLC” at this year’s ISCO!
Prof. Thierry Le Chevalier is a senior expert medical oncologist with a distinguished career at Gustave Roussy Cancer Campus, where he served as Former Head of the Department of Medicine, Former Chief of Service in Medical Oncology, and Former Chairman of the Clinical Trials Committee. He also held an appointment at the Centre Chirurgical Marie Lannelongue in France. A specialist in strategies for the treatment of lung cancer, he is a member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the International Association for the Study of Lung Cancer (IASLC), and the French Cancer Society.
Join us in welcoming Prof. Le Chevalier as he shares his insights and research with us!”
27. “We are thrilled to announce that Prof. Yohann Loriot will be a distinguished speaker in the Genitourinary Session: “Balancing Efficacy and Tolerability: New Treatments in Metastatic Urothelial Carcinoma” at this year’s ISCO!
Prof. Yohann Loriot is a university professor and hospital practitioner at Gustave Roussy Cancer Campus, France, serving as Deputy Head of the Department of Therapeutic Innovation and Early Trials (DITEP) and coordinator of the UNLOCK programme, which focuses on analysing mechanisms of action and resistance to innovative therapies. A specialist in bladder and urothelial cancers, he teaches medicine at the University of Paris-Saclay and holds a medical doctorate from Pierre-et-Marie-Curie University and a PhD in anti-tumour pharmacology from the University of Paris-Saclay. In 2024, he was awarded his Habilitation à Diriger des Recherches (HDR). He joined Gustave Roussy in 2009, spending a year at the Vancouver Prostate Centre studying androgen receptor resistance mechanisms. He received the Conquer Cancer Foundation ASCO Young Investigator Award in 2013 and is responsible for the ESMO European recommendations for bladder tumour management. He leads the EORTC urological tumours research group and has authored more than 300 publications in high-impact journals including the New England Journal of Medicine.
Join us in welcoming Prof. Loriot as he shares his insights and research with us!”
Stay tuned for more updates!
Other articles about ISCO on OncoDaily.
